Xenetic Biosciences, Inc.
XBIO
$3.11
$0.020.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.30% | -25.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.30% | -25.38% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 5.30% | -25.38% | |||
| SG&A Expenses | 5.15% | -24.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.78% | -11.61% | |||
| Operating Income | 19.41% | -14.37% | |||
| Income Before Tax | 21.19% | -13.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.19% | -13.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.19% | -13.57% | |||
| EBIT | 19.41% | -14.37% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 25.00% | 19.69% | |||
| Normalized Basic EPS | 25.00% | 19.69% | |||
| EPS Diluted | 25.00% | 19.69% | |||
| Normalized Diluted EPS | 25.00% | 19.69% | |||
| Average Basic Shares Outstanding | 5.10% | 41.36% | |||
| Average Diluted Shares Outstanding | 5.10% | 41.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||